Connexon Creative Launches Cord Blood News
Cord Blood News is a weekly e-newsletter that keeps members of the cord blood community informed by providing the latest news from all areas of the field, including its science, research, policy, and business.
ImmunoCellular Therapeutics Retains Services of Torrey Pines Institute for Molecular Studies and Renowned Immunologist to Evaluate Lead Product Candidate
ImmunoCellular Therapeutics, Ltd. announced recently that it has retained the services of the Torrey Pines Institute for Molecular Studies in San Diego, CA, to evaluate the immunogenicity of peptides to target cancer stem cells relating to the Company’s lead product candidate ICT-121.
Yissum Licenses Stem Cell Technologies for Spinal Therapy to TheraCell, Inc.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., recently announced that it has licensed a novel package of stem cell related technologies to TheraCell, Inc., which will further develop and commercialize the technology for advanced regenerative medicine procedures such as spinal fusion.
Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis
Alnylam Pharmaceuticals, Inc. announced recently that Novartis has elected to extend the company’s RNAi therapeutics collaboration for a fifth and final planned year, through October 2010.
Case Western Reserve University Receives $5M from Third Frontier Commission for the Center for Stem Cell and Regenerative Medicine
The Center for Stem Cell and Regenerative Medicine, comprised of Case Western Reserve University, Cleveland Clinic, University Hospitals, and Athersys, Inc. has received $5 million from Ohio’s Third Frontier Commission under the Research Commercialization Program.
UK to Channel EUR $21M into Regenerative Medicine
The UK’s Office for Life Sciences will invest EUR $21M into the development of stem cell therapies via its “Life Sciences Blueprint” program.
Cytori’s Celution(R) 700 System to be Regulated as a Medical Device by U.S. FDA
Cytori Therapeutics was informed by the U.S. Food and Drug Administration that the Celution(R) 700 System will be regulated as a medical device under the Federal Food, Drug, and Cosmetic Act.
Canadian Biotechnology Feels the Pinch as Funds Dry Up
Canada will lose up to 7,000 high-skilled research and development jobs within one year if short-term financing cannot be obtained, results from the most recent BIOTECanada survey show
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
Cellular Dynamics International recently announced that it has exclusively in-licensed a US-issued patent portfolio on optimizing the stem cell differentiation selection process and on using heart cells in drug testing.
Cytori Expands Patent Protection for the Celution(R) System and Uses for Adipose Derived Stem and Regenerative Cells
Cytori Therapeutics, Inc. recently received a Notice of Allowance from the U.S. Patent and Trademark Office related to uses of the Celution(R) System for the treatment of bone related disorders.
Aastrom Biosciences Receives Notification That NASDAQ to Continue Temporary Suspension of Certain Continued Listing Requirements
Aastrom Biosciences, Inc. announced that the Company received Issuer Alert #2009-004, which states that NASDAQ is continuing the temporary suspension of the rules requiring a minimum $1.00 per share closing bid price and a minimum market value of publicly held shares for approximately two additional weeks.